文献速递胸部肿瘤

IA至IIIA期EGFR突变非小细胞肺癌的新辅助与辅助奥希替尼治疗(NORA)

Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA).
PubMed 文献 · J Thorac Oncol · 2024-12-26

这项单中心先导研究纳入25例IA至IIIA期EGFR突变可切除非小细胞肺癌患者,接受2周期新辅助奥希替尼后手术及3年辅助奥希替尼。主要终点客观缓解率为44%,未达预设终点;主要病理缓解率24%,病理完全缓解率0%,新辅助期间无3级不良事件。

要点

  • 2周期新辅助奥希替尼的客观缓解率为44%(11例),均为部分缓解,未达主要终点。
  • 主要病理缓解率24%(6例),病理完全缓解率0%,全部患者实现R0切除。
  • 新辅助期间无3级不良事件,中位随访31个月时中位无病生存期未达到。

核心结论

  • 2周期新辅助奥希替尼未达到客观缓解率的主要终点,但在可切除EGFR突变非小细胞肺癌中是可行的方法,安全性可控。

研究设计与样本

  • 单中心先导研究,纳入临床IA至IIIA期(美国癌症联合委员会第八版)携带活化EGFR突变(外显子19缺失、L858R)的非小细胞肺癌患者25例。
  • 患者接受2个28天周期新辅助奥希替尼,随后手术切除,再接受3年辅助奥希替尼。
  • 主要终点为2周期新辅助治疗后的客观缓解率;次要终点包括病理完全缓解率和主要病理缓解率;探索性目标包括纵向循环肿瘤DNA检测(Signatera)与新辅助奥希替尼疗效的相关性。

主要发现

  • 25例患者全部接受新辅助奥希替尼并完成手术切除,均实现R0切除。
  • 客观缓解率为44%(n=11),均为部分缓解;14例(56%)在新辅助奥希替尼后报告疾病稳定。
  • 主要病理缓解率为24%(n=6),病理完全缓解率为0%;无患者接受辅助化疗。
  • 中位随访31个月(范围13.8-38.6个月)时,中位无病生存期未达到。
  • 6例(30%)基线循环肿瘤DNA阳性,在1周期新辅助奥希替尼后实现清除;新辅助治疗期间无3级不良事件。

关键数值与推荐

  • 客观缓解率44%(n=11),均为部分缓解;疾病稳定56%(n=14)。
  • 主要病理缓解率24%(n=6),病理完全缓解率0%。
  • 中位随访31个月(范围13.8-38.6个月)时中位无病生存期未达到。
  • 基线循环肿瘤DNA阳性6例(30%),1周期新辅助奥希替尼后清除。
  • 新辅助治疗期间无3级不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB to IIIA NSCLC harboring EGFR mutations. The role of neoadjuvant osimertinib in the perioperative setting is yet to be elucidated in the NeoADAURA study (NCT04351555). METHODS: This is a single-center, pilot study of patients with clinical stage IA to IIIA NSCLC (American Joint Committee on Cancer eighth edition) harboring an activating EGFR mutation (Exon 19 deletion, L858R) (NCT04816838). Patients were treated with two 28-day cycles of neoadjuvant osimertinib followed by surgical resection and three years of adjuvant osimertinib. The primary endpoint was the objective response rate after two cycles of neoadjuvant treatment. Secondary endpoints included the pathologic complete response rate and major pathologic response rate. Exploratory objectives included the correlation of longitudinal circulating tumor DNA testing (Signatera) and response to neoadjuvant osimertinib. RESULTS: A total of 25 patients were enrolled and treated with neoadjuvant osimertinib, and all patients received surgical resection with R0 resection. The objective response rate was 44% (n = 11) all of which were partial responses. Fourteen patients (56%) reported stable disease after neoadjuvant osimertinib. The major pathologic response and pathologic complete response rates were 24% (n = 6) and 0%, respectively. None of the patients received adjuvant chemotherapy. The median disease-free survival was not reached at a median follow-up of 31 months (range: 13.8-38.6 mo). Six patients (30%) were circulating tumor DNA-positive at baseline and achieved clearance after 1 cycle of neoadjuvant osimertinib. There were no grade 3 adverse events during neoadjuvant treatment. CONCLUSIONS: Two cycles of neoadjuvant osimertinib did not meet its primary endpoint of ORR. Neoadjuvant osimertinib is a feasible approach with a manageable safety profile in resectable EGFR-mutant NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lee JB, Choi SJ, Shim HS, et al. Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA). J Thorac Oncol. 2024. PMID: 39732365. doi:10.1016/j.jtho.2024.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。